<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 19:03:04 -0700</creation_date>
  <update_date>2013-05-27 11:35:00 -0600</update_date>
  <accession>HMDBP02154</accession>
  <secondary_accessions>
    <accession>7637</accession>
    <accession>HMDBP04311</accession>
  </secondary_accessions>
  <protein_type>Transporter</protein_type>
  <synonyms>
    <synonym>NET</synonym>
    <synonym>Norepinephrine transporter</synonym>
    <synonym>Solute carrier family 6 member 2</synonym>
  </synonyms>
  <gene_name>SLC6A2</gene_name>
  <general_function>Involved in neurotransmitter:sodium symporter activity</general_function>
  <specific_function>Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
</specific_function>
  <pathways>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB00588</accession>
      <name>Sodium</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01510</accession>
      <name>Bupropion</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01848</accession>
      <name>Imipramine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05016</accession>
      <name>Venlafaxine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00216</accession>
      <name>Norepinephrine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14337</accession>
      <name>Phentermine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14339</accession>
      <name>Tramadol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14371</accession>
      <name>Guanadrel Sulfate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14379</accession>
      <name>Reboxetine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14434</accession>
      <name>Atomoxetine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14488</accession>
      <name>Protriptyline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14566</accession>
      <name>Methylphenidate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14619</accession>
      <name>Duloxetine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14680</accession>
      <name>Nortriptyline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14683</accession>
      <name>Amoxapine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14718</accession>
      <name>Mazindol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14834</accession>
      <name>Ergotamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14853</accession>
      <name>Paroxetine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14864</accession>
      <name>Trimipramine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14968</accession>
      <name>Phenmetrazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15043</accession>
      <name>Cocaine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15069</accession>
      <name>Maprotiline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15072</accession>
      <name>Diethylpropion</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15237</accession>
      <name>Sibutramine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15273</accession>
      <name>Doxepin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15280</accession>
      <name>Nefazodone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15282</accession>
      <name>Desipramine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15301</accession>
      <name>Guanethidine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15304</accession>
      <name>Orphenadrine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15372</accession>
      <name>Clomipramine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15451</accession>
      <name>Ephedrine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15516</accession>
      <name>Dextroamphetamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15517</accession>
      <name>Methamphetamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15519</accession>
      <name>Phendimetrazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15602</accession>
      <name>Milnacipran</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15620</accession>
      <name>Mianserin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15627</accession>
      <name>Droxidopa</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15646</accession>
      <name>Desvenlafaxine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15647</accession>
      <name>Dexmethylphenidate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15652</accession>
      <name>Levonordefrin</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transmembrane transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>neurotransmitter transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>neurotransmitter:sodium symporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>establishment of localization</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>neurotransmitter transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>cell part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>intrinsic to membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>integral to membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>integral to plasma membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>integral to plasma membrane</description>
      <go_id>GO:0005887</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>norepinephrine:sodium symporter activity</description>
      <go_id>GO:0005334</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>synaptic transmission</description>
      <go_id>GO:0007268</go_id>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Membrane</subcellular_location>
    <subcellular_location>Multi-pass membrane protein</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>16</chromosome_location>
    <locus>16q12.2</locus>
    <gene_sequence>&gt;1854 bp
ATGCTTCTGGCGCGGATGAACCCGCAGGTGCAGCCCGAGAACAACGGGGCGGACACGGGT
CCAGAGCAGCCCCTTCGGGCGCGCAAAACTGCGGAGCTGCTGGTGGTGAAGGAGCGCAAC
GGCGTCCAGTGCCTGCTGGCGCCCCGCGACGGCGACGCGCAGCCCCGGGAGACCTGGGGC
AAGAAGATCGACTTCCTGCTGTCCGTAGTCGGCTTCGCAGTGGACCTGGCCAACGTGTGG
CGCTTCCCCTACCTCTGCTACAAGAACGGCGGCGGTGCCTTCTTGATCCCGTACACACTG
TTCCTTATCATCGCGGGGATGCCCCTGTTCTACATGGAGCTGGCTCTGGGACAGTACAAC
CGGGAGGGGGCTGCCACCGTTTGGAAAATCTGCCCATTCTTCAAAGGCGTTGGCTATGCT
GTCATCCTGATCGCCCTGTACGTTGGCTTCTACTACAACGTCATCATCGCCTGGTCACTC
TACTACCTCTTCTCCTCCTTCACCCTCAACCTGCCCTGGACCGACTGTGGCCACACCTGG
AACAGCCCCAACTGTACCGACCCCAAGCTCCTCAATGGCTCCGTGCTTGGCAACCACACC
AAGTACTCCAAGTACAAGTTCACGCCGGCAGCCGAGTTTTATGAGCGTGGTGTCCTGCAC
CTTCACGAGAGCAGCGGGATTCATGACATCGGCCTGCCCCAGTGGCAGCTCTTGCTCTGT
CTGATGGTCGTCGTCATCGTCTTGTATTTTAGCCTCTGGAAAGGGGTGAAGACATCAGGA
AAGGTGGTGTGGATCACAGCCACGCTGCCTTACTTCGTGCTGTTCGTGCTCCTGGTCCAT
GGCGTCACGCTGCCCGGAGCCTCCAATGGCATCAATGCCTACCTGCACATCGACTTCTAC
CGCTTGAAAGAGGCCACGGTATGGATTGATGCCGCAACTCAGATATTTTTTTCCTTGGGG
GCTGGATTTGGAGTATTGATTGCATTTGCCAGTTACAACAAATTTGACAACAACTGTTAC
AGGGATGCCCTGCTGACCAGCAGCATCAACTGTATCACCAGCTTCGTCTCTGGGTTCGCC
ATCTTCTCCATCCTTGGTTACATGGCCCATGAACACAAGGTCAACATTGAGGATGTGGCC
ACAGAAGGAGCTGGCCTAGTGTTCATCCTGTATCCAGAGGCCATTTCTACCCTGTCTGGA
TCTACATTCTGGGCTGTTGTGTTTTTCGTCATGCTCCTGGCGCTGGGCCTTGACAGCTCA
ATGGGAGGCATGGAGGCTGTCATCACGGGCCTGGCAGATGACTTCCAGGTCCTGAAGCGA
CACCGGAAACTCTTCACATTTGGCGTCACCTTCAGCACTTTCCTTCTCGCCCTGTTCTGC
ATAACCAAGGGTGGAATTTACGTCTTGACCCTCCTGGACACCTTTGCTGCGGGCACCTCC
ATCCTTTTTGCTGTCCTCATGGAAGCCATCGGAGTTTCCTGGTTTTATGGAGTGGACAGG
TTCAGCAACGACATCCAGCAGATGATGGGGTTCAGGCCGGGTCTATACTGGAGACTGTGC
TGGAAGTTCGTCAGTCCTGCCTTCCTCCTGTTCGTGGTTGTGGTCAGCATCATCAACTTC
AAGCCACTCACCTACGACGACTACATCTTCCCGCCCTGGGCCAACTGGGTGGGGTGGGGC
ATCGCCCTGTCCTCCATGGTCCTGGTGCCCATCTACGTCATCTATAAGTTCCTCAGCACG
CAGGGCTCTCTTTGGGAGAGACTGGCCTATGGCATCACGCCAGAGAACGAGCACCACCTG
GTGGCTCAGAGGGACATCAGACAGTTCCAGTTGCAACACTGGCTGGCCATCTGA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>617</residue_number>
    <molecular_weight>69331.42</molecular_weight>
    <theoretical_pi>7.481</theoretical_pi>
    <pfams>
      <pfam>
        <name>SNF</name>
        <pfam_id>PF00209</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
    </transmembrane_regions>
    <signal_regions>
    </signal_regions>
    <protein_sequence>&gt;Sodium-dependent noradrenaline transporter
MLLARMNPQVQPENNGADTGPEQPLRARKTAELLVVKERNGVQCLLAPRDGDAQPRETWG
KKIDFLLSVVGFAVDLANVWRFPYLCYKNGGGAFLIPYTLFLIIAGMPLFYMELALGQYN
REGAATVWKICPFFKGVGYAVILIALYVGFYYNVIIAWSLYYLFSSFTLNLPWTDCGHTW
NSPNCTDPKLLNGSVLGNHTKYSKYKFTPAAEFYERGVLHLHESSGIHDIGLPQWQLLLC
LMVVVIVLYFSLWKGVKTSGKVVWITATLPYFVLFVLLVHGVTLPGASNGINAYLHIDFY
RLKEATVWIDAATQIFFSLGAGFGVLIAFASYNKFDNNCYRDALLTSSINCITSFVSGFA
IFSILGYMAHEHKVNIEDVATEGAGLVFILYPEAISTLSGSTFWAVVFFVMLLALGLDSS
MGGMEAVITGLADDFQVLKRHRKLFTFGVTFSTFLLALFCITKGGIYVLTLLDTFAAGTS
ILFAVLMEAIGVSWFYGVDRFSNDIQQMMGFRPGLYWRLCWKFVSPAFLLFVVVVSIINF
KPLTYDDYIFPPWANWVGWGIALSSMVLVPIYVIYKFLSTQGSLWERLAYGITPENEHHL
VAQRDIRQFQLQHWLAI</protein_sequence>
  </protein_properties>
  <genbank_protein_id/>
  <uniprot_id>P23975</uniprot_id>
  <uniprot_name>SC6A2_HUMAN</uniprot_name>
  <pdb_ids>
  </pdb_ids>
  <genbank_gene_id>M65105</genbank_gene_id>
  <genecard_id>SLC6A2</genecard_id>
  <geneatlas_id>SLC6A2</geneatlas_id>
  <hgnc_id>HGNC:11048</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Pacholczyk T, Blakely RD, Amara SG: Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter. Nature. 1991 Mar 28;350(6316):350-4.</reference_text>
      <pubmed_id>2008212</pubmed_id>
    </reference>
    <reference>
      <reference_text>Porzgen P, Bonisch H, Bruss M: Molecular cloning and organization of the coding region of the human norepinephrine transporter gene. Biochem Biophys Res Commun. 1995 Oct 24;215(3):1145-50.</reference_text>
      <pubmed_id>7488042</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21.</reference_text>
      <pubmed_id>14702039</pubmed_id>
    </reference>
    <reference>
      <reference_text>Torres GE, Yao WD, Mohn AR, Quan H, Kim KM, Levey AI, Staudinger J, Caron MG: Functional interaction between monoamine plasma membrane transporters and the synaptic PDZ domain-containing protein PICK1. Neuron. 2001 Apr;30(1):121-34.</reference_text>
      <pubmed_id>11343649</pubmed_id>
    </reference>
    <reference>
      <reference_text>Shannon JR, Flattem NL, Jordan J, Jacob G, Black BK, Biaggioni I, Blakely RD, Robertson D: Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency. N Engl J Med. 2000 Feb 24;342(8):541-9.</reference_text>
      <pubmed_id>10684912</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Norepinephrine</name>
        <accession>HMDB00216</accession>
      </metabolite>
      <reference>
        <reference_text>Habecker BA, Willison BD, Shi X, Woodward WR: Chronic depolarization stimulates norepinephrine transporter expression via catecholamines. J Neurochem. 2006 May;97(4):1044-51. Epub 2006 Mar 29.</reference_text>
        <pubmed_id>16573647</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norepinephrine</name>
        <accession>HMDB00216</accession>
      </metabolite>
      <reference>
        <reference_text>Bonisch H, Bruss M: The norepinephrine transporter in physiology and disease.  Handb Exp Pharmacol. 2006;(175):485-524.</reference_text>
        <pubmed_id>16722247</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norepinephrine</name>
        <accession>HMDB00216</accession>
      </metabolite>
      <reference>
        <reference_text>Mandela P, Ordway GA: KCl stimulation increases norepinephrine transporter function in PC12 cells.  J Neurochem. 2006 Sep;98(5):1521-30. Epub 2006 Jul 31.</reference_text>
        <pubmed_id>16879714</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norepinephrine</name>
        <accession>HMDB00216</accession>
      </metabolite>
      <reference>
        <reference_text>Gutman DA, Owens MJ: Serotonin and norepinephrine transporter binding profile of SSRIs.  Essent Psychopharmacol. 2006;7(1):35-41.</reference_text>
        <pubmed_id>16989291</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norepinephrine</name>
        <accession>HMDB00216</accession>
      </metabolite>
      <reference>
        <reference_text>Ksiazek P, Buraczynska K, Buraczynska M: Norepinephrine transporter gene (NET) polymorphism in patients with type 2 diabetes. Kidney Blood Press Res. 2006;29(6):338-43. Epub 2006 Nov 23.</reference_text>
        <pubmed_id>17124432</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phentermine</name>
        <accession>HMDB14337</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phentermine</name>
        <accession>HMDB14337</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phentermine</name>
        <accession>HMDB14337</accession>
      </metabolite>
      <reference>
        <reference_text>Stephens LC, Katz SG: Phentermine and anaesthesia.  Anaesth Intensive Care. 2005 Aug;33(4):525-7.</reference_text>
        <pubmed_id>16119498</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phentermine</name>
        <accession>HMDB14337</accession>
      </metabolite>
      <reference>
        <reference_text>Samanin R, Garattini S: Neurochemical mechanism of action of anorectic drugs.  Pharmacol Toxicol. 1993 Aug;73(2):63-8.</reference_text>
        <pubmed_id>7902561</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phentermine</name>
        <accession>HMDB14337</accession>
      </metabolite>
      <reference>
        <reference_text>Proietto J, Fam BC, Ainslie DA, Thorburn AW: Novel anti-obesity drugs.  Expert Opin Investig Drugs. 2000 Jun;9(6):1317-26.</reference_text>
        <pubmed_id>11060745</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tramadol</name>
        <accession>HMDB14339</accession>
      </metabolite>
      <reference>
        <reference_text>Sagata K, Minami K, Yanagihara N, Shiraishi M, Toyohira Y, Ueno S, Shigematsu A: Tramadol inhibits norepinephrine transporter function at desipramine-binding sites in cultured bovine adrenal medullary cells. Anesth Analg. 2002 Apr;94(4):901-6, table of contents.</reference_text>
        <pubmed_id>11916794</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tramadol</name>
        <accession>HMDB14339</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tramadol</name>
        <accession>HMDB14339</accession>
      </metabolite>
      <reference>
        <reference_text>Berrocoso E, Mico JA: Cooperative opioid and serotonergic mechanisms generate superior antidepressant-like effects in a mice model of depression. Int J Neuropsychopharmacol. 2009 Sep;12(8):1033-44. Epub 2009 Apr 3.</reference_text>
        <pubmed_id>19341511</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tramadol</name>
        <accession>HMDB14339</accession>
      </metabolite>
      <reference>
        <reference_text>Frink MC, Hennies HH, Englberger W, Haurand M, Wilffert B: Influence of tramadol on neurotransmitter systems of the rat brain.  Arzneimittelforschung. 1996 Nov;46(11):1029-36.</reference_text>
        <pubmed_id>8955860</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Guanadrel Sulfate</name>
        <accession>HMDB14371</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Guanadrel Sulfate</name>
        <accession>HMDB14371</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Guanadrel Sulfate</name>
        <accession>HMDB14371</accession>
      </metabolite>
      <reference>
        <reference_text>Malinow SH: Comparison of guanadrel and guanethidine efficacy and side effects.  Clin Ther. 1983;5(3):284-9.</reference_text>
        <pubmed_id>6850722</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Guanadrel Sulfate</name>
        <accession>HMDB14371</accession>
      </metabolite>
      <reference>
        <reference_text>Finnerty FA Jr, Brogden RN: Guanadrel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension. Drugs. 1985 Jul;30(1):22-31.</reference_text>
        <pubmed_id>3896742</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Guanadrel Sulfate</name>
        <accession>HMDB14371</accession>
      </metabolite>
      <reference>
        <reference_text>Palmer JD, Nugent CA: Guanadrel sulfate: a postganglionic sympathetic inhibitor for the treatment of mild to moderate hypertension. Pharmacotherapy. 1983 Jul-Aug;3(4):220-9.</reference_text>
        <pubmed_id>6351026</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Reboxetine</name>
        <accession>HMDB14379</accession>
      </metabolite>
      <reference>
        <reference_text>Rauhut AS, Mullins SN, Dwoskin LP, Bardo MT: Reboxetine: attenuation of intravenous nicotine self-administration in rats.  J Pharmacol Exp Ther. 2002 Nov;303(2):664-72.</reference_text>
        <pubmed_id>12388649</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Reboxetine</name>
        <accession>HMDB14379</accession>
      </metabolite>
      <reference>
        <reference_text>Wilson AA, Johnson DP, Mozley D, Hussey D, Ginovart N, Nobrega J, Garcia A, Meyer J, Houle S: Synthesis and in vivo evaluation of novel radiotracers for the in vivo imaging of the norepinephrine transporter. Nucl Med Biol. 2003 Feb;30(2):85-92.</reference_text>
        <pubmed_id>12623106</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Reboxetine</name>
        <accession>HMDB14379</accession>
      </metabolite>
      <reference>
        <reference_text>Lin KS, Ding YS, Kim SW, Kil KE: Synthesis, enantiomeric resolution, F-18 labeling and biodistribution of reboxetine analogs: promising radioligands for imaging the norepinephrine transporter with positron emission tomography. Nucl Med Biol. 2005 May;32(4):415-22.</reference_text>
        <pubmed_id>15878511</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Reboxetine</name>
        <accession>HMDB14379</accession>
      </metabolite>
      <reference>
        <reference_text>Spivak B, Strous RD, Shaked G, Shabash E, Kotler M, Weizman A: Reboxetine versus fluvoxamine in the treatment of motor vehicle accident-related posttraumatic stress disorder: a double-blind, fixed-dosage, controlled trial. J Clin Psychopharmacol. 2006 Apr;26(2):152-6.</reference_text>
        <pubmed_id>16633143</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Reboxetine</name>
        <accession>HMDB14379</accession>
      </metabolite>
      <reference>
        <reference_text>Mitchell HA, Ahern TH, Liles LC, Javors MA, Weinshenker D: The effects of norepinephrine transporter inactivation on locomotor activity in mice. Biol Psychiatry. 2006 Nov 15;60(10):1046-52. Epub 2006 Aug 7.</reference_text>
        <pubmed_id>16893531</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Reboxetine</name>
        <accession>HMDB14379</accession>
      </metabolite>
      <reference>
        <reference_text>Kasper S, el Giamal N, Hilger E: Reboxetine: the first selective noradrenaline re-uptake inhibitor.  Expert Opin Pharmacother. 2000 May;1(4):771-82.</reference_text>
        <pubmed_id>11249515</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Atomoxetine</name>
        <accession>HMDB14434</accession>
      </metabolite>
      <reference>
        <reference_text>Biederman J, Heiligenstein JH, Faries DE, Galil N, Dittmann R, Emslie GJ, Kratochvil CJ, Laws HF, Schuh KJ: Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder. Pediatrics. 2002 Dec;110(6):e75.</reference_text>
        <pubmed_id>12456942</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Atomoxetine</name>
        <accession>HMDB14434</accession>
      </metabolite>
      <reference>
        <reference_text>Spencer T, Heiligenstein JH, Biederman J, Faries DE, Kratochvil CJ, Conners CK, Potter WZ: Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002 Dec;63(12):1140-7.</reference_text>
        <pubmed_id>12523874</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Atomoxetine</name>
        <accession>HMDB14434</accession>
      </metabolite>
      <reference>
        <reference_text>Michelson D, Adler L, Spencer T, Reimherr FW, West SA, Allen AJ, Kelsey D, Wernicke J, Dietrich A, Milton D: Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies.  Biol Psychiatry. 2003 Jan 15;53(2):112-20.</reference_text>
        <pubmed_id>12547466</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Atomoxetine</name>
        <accession>HMDB14434</accession>
      </metabolite>
      <reference>
        <reference_text>Wernicke JF, Faries D, Girod D, Brown J, Gao H, Kelsey D, Quintana H, Lipetz R, Michelson D, Heiligenstein J: Cardiovascular effects of atomoxetine in children, adolescents, and adults.  Drug Saf. 2003;26(10):729-40.</reference_text>
        <pubmed_id>12862507</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Atomoxetine</name>
        <accession>HMDB14434</accession>
      </metabolite>
      <reference>
        <reference_text>Wernicke JF, Adler L, Spencer T, West SA, Allen AJ, Heiligenstein J, Milton D, Ruff D, Brown WJ, Kelsey D, Michelson D: Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment. J Clin Psychopharmacol. 2004 Feb;24(1):30-5.</reference_text>
        <pubmed_id>14709944</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Atomoxetine</name>
        <accession>HMDB14434</accession>
      </metabolite>
      <reference>
        <reference_text>Garnock-Jones KP, Keating GM: Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005.</reference_text>
        <pubmed_id>19445548</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Atomoxetine</name>
        <accession>HMDB14434</accession>
      </metabolite>
      <reference>
        <reference_text>Kaplan S, Heiligenstein J, West S, Busner J, Harder D, Dittmann R, Casat C, Wernicke JF: Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder. J Atten Disord. 2004 Oct;8(2):45-52.</reference_text>
        <pubmed_id>15801334</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Atomoxetine</name>
        <accession>HMDB14434</accession>
      </metabolite>
      <reference>
        <reference_text>Purper-Ouakil D, Fourneret P, Wohl M, Reneric JP: [Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents]. Encephale. 2005 May-Jun;31(3):337-48.</reference_text>
        <pubmed_id>16142049</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Atomoxetine</name>
        <accession>HMDB14434</accession>
      </metabolite>
      <reference>
        <reference_text>Gaillez C, Sorbara F, Perrin E: [Atomoxetine (Strattera), an alternative in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children]. Encephale. 2007 Sep;33(4 Pt 1):621-8.</reference_text>
        <pubmed_id>18033153</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Atomoxetine</name>
        <accession>HMDB14434</accession>
      </metabolite>
      <reference>
        <reference_text>Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58.</reference_text>
        <pubmed_id>9537821</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Protriptyline</name>
        <accession>HMDB14488</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Protriptyline</name>
        <accession>HMDB14488</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Protriptyline</name>
        <accession>HMDB14488</accession>
      </metabolite>
      <reference>
        <reference_text>Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58.</reference_text>
        <pubmed_id>9537821</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Protriptyline</name>
        <accession>HMDB14488</accession>
      </metabolite>
      <reference>
        <reference_text>Cheetham SC, Viggers JA, Butler SA, Prow MR, Heal DJ: [3H]nisoxetine--a radioligand for noradrenaline reuptake sites: correlation with inhibition of [3H]noradrenaline uptake and effect of DSP-4 lesioning and antidepressant treatments. Neuropharmacology. 1996 Jan;35(1):63-70.</reference_text>
        <pubmed_id>8684598</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methylphenidate</name>
        <accession>HMDB14566</accession>
      </metabolite>
      <reference>
        <reference_text>Yang L, Wang YF, Li J, Faraone SV: Association of norepinephrine transporter gene with methylphenidate response.  J Am Acad Child Adolesc Psychiatry. 2004 Sep;43(9):1154-8.</reference_text>
        <pubmed_id>15322419</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methylphenidate</name>
        <accession>HMDB14566</accession>
      </metabolite>
      <reference>
        <reference_text>Williard RL, Middaugh LD, Zhu HJ, Patrick KS: Methylphenidate and its ethanol transesterification metabolite ethylphenidate: brain disposition, monoamine transporters and motor activity. Behav Pharmacol. 2007 Feb;18(1):39-51.</reference_text>
        <pubmed_id>17218796</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methylphenidate</name>
        <accession>HMDB14566</accession>
      </metabolite>
      <reference>
        <reference_text>Chuhan YS, Taukulis HK: Impairment of single-trial memory formation by oral methylphenidate in the rat.  Neurobiol Learn Mem. 2006 Mar;85(2):125-31. Epub 2005 Oct 24.</reference_text>
        <pubmed_id>16246598</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methylphenidate</name>
        <accession>HMDB14566</accession>
      </metabolite>
      <reference>
        <reference_text>Gray JD, Punsoni M, Tabori NE, Melton JT, Fanslow V, Ward MJ, Zupan B, Menzer D, Rice J, Drake CT, Romeo RD, Brake WG, Torres-Reveron A, Milner TA: Methylphenidate administration to juvenile rats alters brain areas involved in cognition, motivated behaviors, appetite, and stress. J Neurosci. 2007 Jul 4;27(27):7196-207.</reference_text>
        <pubmed_id>17611273</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methylphenidate</name>
        <accession>HMDB14566</accession>
      </metabolite>
      <reference>
        <reference_text>Sandoval V, Riddle EL, Ugarte YV, Hanson GR, Fleckenstein AE: Methamphetamine-induced rapid and reversible changes in dopamine transporter function: an in vitro model. J Neurosci. 2001 Feb 15;21(4):1413-9.</reference_text>
        <pubmed_id>11160413</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methylphenidate</name>
        <accession>HMDB14566</accession>
      </metabolite>
      <reference>
        <reference_text>Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58.</reference_text>
        <pubmed_id>9537821</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methylphenidate</name>
        <accession>HMDB14566</accession>
      </metabolite>
      <reference>
        <reference_text>Tilley MR, Gu HH: The effects of methylphenidate on knockin mice with a methylphenidate-resistant dopamine transporter. J Pharmacol Exp Ther. 2008 Nov;327(2):554-60. Epub 2008 Aug 12.</reference_text>
        <pubmed_id>18698001</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Duloxetine</name>
        <accession>HMDB14619</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Duloxetine</name>
        <accession>HMDB14619</accession>
      </metabolite>
      <reference>
        <reference_text>Gould GG, Javors MA, Frazer A: Effect of Chronic Administration of Duloxetine on Serotonin and Norepinephrine Transporter Binding Sites in Rat Brain. Biol Psychiatry. 2006 Apr 29;.</reference_text>
        <pubmed_id>16650830</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Duloxetine</name>
        <accession>HMDB14619</accession>
      </metabolite>
      <reference>
        <reference_text>Vaishnavi SN, Nemeroff CB, Plott SJ, Rao SG, Kranzler J, Owens MJ: Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry. 2004 Feb 1;55(3):320-2.</reference_text>
        <pubmed_id>14744476</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Duloxetine</name>
        <accession>HMDB14619</accession>
      </metabolite>
      <reference>
        <reference_text>Beique JC, Lavoie N, de Montigny C, Debonnel G: Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters. Eur J Pharmacol. 1998 May 15;349(1):129-32.</reference_text>
        <pubmed_id>9669506</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Duloxetine</name>
        <accession>HMDB14619</accession>
      </metabolite>
      <reference>
        <reference_text>Vincent S, Bieck PR, Garland EM, Loghin C, Bymaster FP, Black BK, Gonzales C, Potter WZ, Robertson D: Clinical assessment of norepinephrine transporter blockade through biochemical and pharmacological profiles. Circulation. 2004 Jun 29;109(25):3202-7. Epub 2004 Jun 7.</reference_text>
        <pubmed_id>15184278</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Duloxetine</name>
        <accession>HMDB14619</accession>
      </metabolite>
      <reference>
        <reference_text>Schou M, Halldin C, Pike VW, Mozley PD, Dobson D, Innis RB, Farde L, Hall H: Post-mortem human brain autoradiography of the norepinephrine transporter using (S,S)-[18F]FMeNER-D2. Eur Neuropsychopharmacol. 2005 Oct;15(5):517-20. Epub 2005 Apr 7.</reference_text>
        <pubmed_id>16139169</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Duloxetine</name>
        <accession>HMDB14619</accession>
      </metabolite>
      <reference>
        <reference_text>Mirza NR, Nielsen EO, Troelsen KB: Serotonin transporter density and anxiolytic-like effects of antidepressants in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2007 May 9;31(4):858-66. Epub 2007 Jan       30.</reference_text>
        <pubmed_id>17335951</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Duloxetine</name>
        <accession>HMDB14619</accession>
      </metabolite>
      <reference>
        <reference_text>Karpa KD, Cavanaugh JE, Lakoski JM: Duloxetine pharmacology: profile of a dual monoamine modulator.  CNS Drug Rev. 2002 Winter;8(4):361-76.</reference_text>
        <pubmed_id>12481192</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Duloxetine</name>
        <accession>HMDB14619</accession>
      </metabolite>
      <reference>
        <reference_text>van Groeningen CJ, Peters GJ, Pinedo HM: Lack of effectiveness of combined 5-fluorouracil and leucovorin in patients with 5-fluorouracil-resistant advanced colorectal cancer. Eur J Cancer Clin Oncol. 1989 Jan;25(1):45-9.</reference_text>
        <pubmed_id>2784100</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Duloxetine</name>
        <accession>HMDB14619</accession>
      </metabolite>
      <reference>
        <reference_text>Jost W, Marsalek P: Duloxetine: mechanism of action at the lower urinary tract and Onuf's nucleus.  Clin Auton Res. 2004 Aug;14(4):220-7.</reference_text>
        <pubmed_id>15316838</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Duloxetine</name>
        <accession>HMDB14619</accession>
      </metabolite>
      <reference>
        <reference_text>Trivedi MH, Desaiah D, Ossanna MJ, Pritchett YL, Brannan SK, Detke MJ: Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine. Int Clin Psychopharmacol. 2008 May;23(3):161-9.</reference_text>
        <pubmed_id>18408530</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Duloxetine</name>
        <accession>HMDB14619</accession>
      </metabolite>
      <reference>
        <reference_text>Bymaster FP, Lee TC, Knadler MP, Detke MJ, Iyengar S: The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression. Curr Pharm Des. 2005;11(12):1475-93.</reference_text>
        <pubmed_id>15892657</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Duloxetine</name>
        <accession>HMDB14619</accession>
      </metabolite>
      <reference>
        <reference_text>Khullar V, Cardozo L, Dmochowski R: Mixed incontinence: current evidence and future perspectives.  Neurourol Urodyn. 2010 Apr;29(4):618-22.</reference_text>
        <pubmed_id>20432324</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Duloxetine</name>
        <accession>HMDB14619</accession>
      </metabolite>
      <reference>
        <reference_text>Carter NJ, McCormack PL: Duloxetine: a review of its use in the treatment of generalized anxiety disorder.  CNS Drugs. 2009;23(6):523-41. doi: 10.2165/00023210-200923060-00006.</reference_text>
        <pubmed_id>19480470</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Duloxetine</name>
        <accession>HMDB14619</accession>
      </metabolite>
      <reference>
        <reference_text>Hunziker ME, Suehs BT, Bettinger TL, Crismon ML: Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder. Clin Ther. 2005 Aug;27(8):1126-43.</reference_text>
        <pubmed_id>16199241</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nortriptyline</name>
        <accession>HMDB14680</accession>
      </metabolite>
      <reference>
        <reference_text>Roubert C, Cox PJ, Bruss M, Hamon M, Bonisch H, Giros B: Determination of residues in the norepinephrine transporter that are critical for tricyclic antidepressant affinity. J Biol Chem. 2001 Mar 16;276(11):8254-60. Epub 2000 Nov 22.</reference_text>
        <pubmed_id>11092898</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nortriptyline</name>
        <accession>HMDB14680</accession>
      </metabolite>
      <reference>
        <reference_text>Roubert C, Sagne C, Kapsimali M, Vernier P, Bourrat F, Giros B: A Na(+)/Cl(-)-dependent transporter for catecholamines, identified as a norepinephrine transporter, is expressed in the brain of the teleost fish medaka (Oryzias latipes). Mol Pharmacol. 2001 Sep;60(3):462-73.</reference_text>
        <pubmed_id>11502876</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nortriptyline</name>
        <accession>HMDB14680</accession>
      </metabolite>
      <reference>
        <reference_text>Vaishnavi SN, Nemeroff CB, Plott SJ, Rao SG, Kranzler J, Owens MJ: Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry. 2004 Feb 1;55(3):320-2.</reference_text>
        <pubmed_id>14744476</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nortriptyline</name>
        <accession>HMDB14680</accession>
      </metabolite>
      <reference>
        <reference_text>Kim H, Lim SW, Kim S, Kim JW, Chang YH, Carroll BJ, Kim DK: Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression. JAMA. 2006 Oct 4;296(13):1609-18.</reference_text>
        <pubmed_id>17018806</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nortriptyline</name>
        <accession>HMDB14680</accession>
      </metabolite>
      <reference>
        <reference_text>Barker EL, Blakely RD: Identification of a single amino acid, phenylalanine 586, that is responsible for high affinity interactions of tricyclic antidepressants with the human serotonin transporter. Mol Pharmacol. 1996 Oct;50(4):957-65.</reference_text>
        <pubmed_id>8863842</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nortriptyline</name>
        <accession>HMDB14680</accession>
      </metabolite>
      <reference>
        <reference_text>Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58.</reference_text>
        <pubmed_id>9537821</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Amoxapine</name>
        <accession>HMDB14683</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Amoxapine</name>
        <accession>HMDB14683</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Amoxapine</name>
        <accession>HMDB14683</accession>
      </metabolite>
      <reference>
        <reference_text>Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58.</reference_text>
        <pubmed_id>9537821</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mazindol</name>
        <accession>HMDB14718</accession>
      </metabolite>
      <reference>
        <reference_text>Raffel DM, Chen W: Binding of [3H]mazindol to cardiac norepinephrine transporters: kinetic and equilibrium studies. Naunyn Schmiedebergs Arch Pharmacol. 2004 Jul;370(1):9-16. Epub 2004 Jul 22.</reference_text>
        <pubmed_id>15300361</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mazindol</name>
        <accession>HMDB14718</accession>
      </metabolite>
      <reference>
        <reference_text>Raffel DM, Chen W, Sherman PS, Gildersleeve DL, Jung YW: Dependence of cardiac 11C-meta-hydroxyephedrine retention on norepinephrine transporter density. J Nucl Med. 2006 Sep;47(9):1490-6.</reference_text>
        <pubmed_id>16954558</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mazindol</name>
        <accession>HMDB14718</accession>
      </metabolite>
      <reference>
        <reference_text>Zhao L, Johnson KM, Zhang M, Flippen-Anderson J, Kozikowski AP: Chemical synthesis and pharmacology of 6- and 7-hydroxylated 2-carbomethoxy-3-(p-tolyl)tropanes: antagonism of cocaine's locomotor stimulant effects. J Med Chem. 2000 Aug 24;43(17):3283-94.</reference_text>
        <pubmed_id>10966747</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mazindol</name>
        <accession>HMDB14718</accession>
      </metabolite>
      <reference>
        <reference_text>Ritz MC, Boja JW, Grigoriadis D, Zaczek R, Carroll FI, Lewis AH, Kuhar MJ: [3H]WIN 35,065-2: a ligand for cocaine receptors in striatum.  J Neurochem. 1990 Nov;55(5):1556-62.</reference_text>
        <pubmed_id>2120386</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mazindol</name>
        <accession>HMDB14718</accession>
      </metabolite>
      <reference>
        <reference_text>Sharpe IA, Palant E, Schroeder CI, Kaye DM, Adams DJ, Alewood PF, Lewis RJ: Inhibition of the norepinephrine transporter by the venom peptide chi-MrIA. Site of action, Na+ dependence, and structure-activity relationship. J Biol Chem. 2003 Oct 10;278(41):40317-23. Epub 2003 Jul 28.</reference_text>
        <pubmed_id>12885787</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mazindol</name>
        <accession>HMDB14718</accession>
      </metabolite>
      <reference>
        <reference_text>Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58.</reference_text>
        <pubmed_id>9537821</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ergotamine</name>
        <accession>HMDB14834</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ergotamine</name>
        <accession>HMDB14834</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paroxetine</name>
        <accession>HMDB14853</accession>
      </metabolite>
      <reference>
        <reference_text>Rubin RT: Paroxetine binding to the rat norepinephrine transporter in vivo.  Biol Psychiatry. 2000 Nov 1;48(9):954-6.</reference_text>
        <pubmed_id>11203183</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paroxetine</name>
        <accession>HMDB14853</accession>
      </metabolite>
      <reference>
        <reference_text>Gilmor ML, Owens MJ, Nemeroff CB: Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine. Am J Psychiatry. 2002 Oct;159(10):1702-10.</reference_text>
        <pubmed_id>12359676</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paroxetine</name>
        <accession>HMDB14853</accession>
      </metabolite>
      <reference>
        <reference_text>Nemeroff CB, Owens MJ: Neuropharmacology of paroxetine.  Psychopharmacol Bull. 2003 Spring;37 Suppl 1:8-18.</reference_text>
        <pubmed_id>14566196</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paroxetine</name>
        <accession>HMDB14853</accession>
      </metabolite>
      <reference>
        <reference_text>Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58.</reference_text>
        <pubmed_id>9537821</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trimipramine</name>
        <accession>HMDB14864</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trimipramine</name>
        <accession>HMDB14864</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenmetrazine</name>
        <accession>HMDB14968</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenmetrazine</name>
        <accession>HMDB14968</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenmetrazine</name>
        <accession>HMDB14968</accession>
      </metabolite>
      <reference>
        <reference_text>Rothman RB, Katsnelson M, Vu N, Partilla JS, Dersch CM, Blough BE, Baumann MH: Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. Eur J Pharmacol. 2002 Jun 28;447(1):51-7.</reference_text>
        <pubmed_id>12106802</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenmetrazine</name>
        <accession>HMDB14968</accession>
      </metabolite>
      <reference>
        <reference_text>Rothman RB, Baumann MH: Therapeutic potential of monoamine transporter substrates.  Curr Top Med Chem. 2006;6(17):1845-59.</reference_text>
        <pubmed_id>17017961</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cocaine</name>
        <accession>HMDB15043</accession>
      </metabolite>
      <reference>
        <reference_text>Galli A, DeFelice LJ, Duke BJ, Moore KR, Blakely RD: Sodium-dependent norepinephrine-induced currents in norepinephrine-transporter-transfected HEK-293 cells blocked by cocaine and antidepressants. J Exp Biol. 1995 Oct;198(Pt 10):2197-212.</reference_text>
        <pubmed_id>7500004</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cocaine</name>
        <accession>HMDB15043</accession>
      </metabolite>
      <reference>
        <reference_text>Burchett SA, Bannon MJ: Serotonin, dopamine and norepinephrine transporter mRNAs: heterogeneity of distribution and response to 'binge' cocaine administration. Brain Res Mol Brain Res. 1997 Oct 3;49(1-2):95-102.</reference_text>
        <pubmed_id>9387868</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cocaine</name>
        <accession>HMDB15043</accession>
      </metabolite>
      <reference>
        <reference_text>Zhao Y, Sun L: Perinatal cocaine exposure reduces myocardial norepinephrine transporter function in the neonatal rat. Neurotoxicol Teratol. 2004 May-Jun;26(3):443-50.</reference_text>
        <pubmed_id>15113605</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cocaine</name>
        <accession>HMDB15043</accession>
      </metabolite>
      <reference>
        <reference_text>Carrera MR, Meijler MM, Janda KD: Cocaine pharmacology and current pharmacotherapies for its abuse.  Bioorg Med Chem. 2004 Oct 1;12(19):5019-30.</reference_text>
        <pubmed_id>15351386</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Maprotiline</name>
        <accession>HMDB15069</accession>
      </metabolite>
      <reference>
        <reference_text>Saba W, Valette H, Schollhorn-Peyronneau MA, Coulon C, Ottaviani M, Chalon S, Dolle F, Emond P, Halldin C, Helfenbein J, Madelmont JC, Deloye JB, Guilloteau D, Bottlaender M: [11C]LBT-999: a suitable radioligand for investigation of extra-striatal dopamine transporter with PET. Synapse. 2007 Jan;61(1):17-23.</reference_text>
        <pubmed_id>17068778</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Maprotiline</name>
        <accession>HMDB15069</accession>
      </metabolite>
      <reference>
        <reference_text>Arai S, Morita K, Kitayama S, Kumagai K, Kumagai M, Kihira K, Dohi T: Chronic inhibition of the norepinephrine transporter in the brain participates in seizure sensitization to cocaine and local anesthetics. Brain Res. 2003 Feb 21;964(1):83-90.</reference_text>
        <pubmed_id>12573515</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Maprotiline</name>
        <accession>HMDB15069</accession>
      </metabolite>
      <reference>
        <reference_text>Cloonan SM, Drozgowska A, Fayne D, Williams DC: The antidepressants maprotiline and fluoxetine have potent selective antiproliferative effects against Burkitt lymphoma independently of the norepinephrine and serotonin transporters. Leuk Lymphoma. 2010 Mar;51(3):523-39.</reference_text>
        <pubmed_id>20141432</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Maprotiline</name>
        <accession>HMDB15069</accession>
      </metabolite>
      <reference>
        <reference_text>Dronjak S, Spasojevic N, Gavrilovic L, Varagic V: Effects of noradrenaline and serotonin reuptake inhibitors on pituitary-adrenocortical and sympatho-adrenomedullar system of adult rats. Neuro Endocrinol Lett. 2007 Oct;28(5):614-20.</reference_text>
        <pubmed_id>17984940</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Maprotiline</name>
        <accession>HMDB15069</accession>
      </metabolite>
      <reference>
        <reference_text>Mochizucki D: Serotonin and noradrenaline reuptake inhibitors in animal models of pain.  Hum Psychopharmacol. 2004 Oct;19 Suppl 1:S15-9.</reference_text>
        <pubmed_id>15378668</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diethylpropion</name>
        <accession>HMDB15072</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diethylpropion</name>
        <accession>HMDB15072</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diethylpropion</name>
        <accession>HMDB15072</accession>
      </metabolite>
      <reference>
        <reference_text>Arias HR, Santamaria A, Ali SF: Pharmacological and neurotoxicological actions mediated by bupropion and diethylpropion. Int Rev Neurobiol. 2009;88:223-55.</reference_text>
        <pubmed_id>19897080</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sibutramine</name>
        <accession>HMDB15237</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sibutramine</name>
        <accession>HMDB15237</accession>
      </metabolite>
      <reference>
        <reference_text>Heusser K, Engeli S, Tank J, Diedrich A, Wiesner S, Janke J, Luft FC, Jordan J: Sympathetic vasomotor tone determines blood pressure response to long-term sibutramine treatment. J Clin Endocrinol Metab. 2007 Apr;92(4):1560-3. Epub 2007 Feb 6.</reference_text>
        <pubmed_id>17284621</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sibutramine</name>
        <accession>HMDB15237</accession>
      </metabolite>
      <reference>
        <reference_text>Jordan J, Scholze J, Matiba B, Wirth A, Hauner H, Sharma AM: Influence of Sibutramine on blood pressure: evidence from placebo-controlled trials. Int J Obes (Lond). 2005 May;29(5):509-16.</reference_text>
        <pubmed_id>15685250</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sibutramine</name>
        <accession>HMDB15237</accession>
      </metabolite>
      <reference>
        <reference_text>Heusser K, Tank J, Diedrich A, Engeli S, Klaua S, Kruger N, Strauss A, Stoffels G, Luft FC, Jordan J: Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects. Clin Pharmacol Ther. 2006 May;79(5):500-8.</reference_text>
        <pubmed_id>16678551</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sibutramine</name>
        <accession>HMDB15237</accession>
      </metabolite>
      <reference>
        <reference_text>Birkenfeld AL, Schroeder C, Boschmann M, Tank J, Franke G, Luft FC, Biaggioni I, Sharma AM, Jordan J: Paradoxical effect of sibutramine on autonomic cardiovascular regulation.  Circulation. 2002 Nov 5;106(19):2459-65.</reference_text>
        <pubmed_id>12417543</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sibutramine</name>
        <accession>HMDB15237</accession>
      </metabolite>
      <reference>
        <reference_text>Birkenfeld AL, Schroeder C, Pischon T, Tank J, Luft FC, Sharma AM, Jordan J: Paradoxical effect of sibutramine on autonomic cardiovascular regulation in obese hypertensive patients--sibutramine and blood pressure. Clin Auton Res. 2005 Jun;15(3):200-6.</reference_text>
        <pubmed_id>15944869</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sibutramine</name>
        <accession>HMDB15237</accession>
      </metabolite>
      <reference>
        <reference_text>Tziomalos K, Krassas GE, Tzotzas T: The use of sibutramine in the management of obesity and related disorders: an update. Vasc Health Risk Manag. 2009;5(1):441-52.</reference_text>
        <pubmed_id>19475780</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sibutramine</name>
        <accession>HMDB15237</accession>
      </metabolite>
      <reference>
        <reference_text>Sharma B, Henderson DC: Sibutramine: current status as an anti-obesity drug and its future perspectives.  Expert Opin Pharmacother. 2008 Aug;9(12):2161-73.</reference_text>
        <pubmed_id>18671470</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sibutramine</name>
        <accession>HMDB15237</accession>
      </metabolite>
      <reference>
        <reference_text>Gomis Barbara R: [Pharmacological treatment of obesity].  Rev Med Univ Navarra. 2004 Apr-Jun;48(2):63-5.</reference_text>
        <pubmed_id>15382615</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sibutramine</name>
        <accession>HMDB15237</accession>
      </metabolite>
      <reference>
        <reference_text>Berke EM, Morden NE: Medical management of obesity.  Am Fam Physician. 2000 Jul 15;62(2):419-26.</reference_text>
        <pubmed_id>10929704</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sibutramine</name>
        <accession>HMDB15237</accession>
      </metabolite>
      <reference>
        <reference_text>Krahn LE, Moore WR, Altchuler SI: Narcolepsy and obesity: remission of severe cataplexy with sibutramine.  Sleep Med. 2001 Jan;2(1):63-65.</reference_text>
        <pubmed_id>11152984</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxepin</name>
        <accession>HMDB15273</accession>
      </metabolite>
      <reference>
        <reference_text>Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58.</reference_text>
        <pubmed_id>9537821</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxepin</name>
        <accession>HMDB15273</accession>
      </metabolite>
      <reference>
        <reference_text>Stahl SM: Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr. 2008 Dec;13(12):1027-38.</reference_text>
        <pubmed_id>19179941</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nefazodone</name>
        <accession>HMDB15280</accession>
      </metabolite>
      <reference>
        <reference_text>Owens MJ, Ieni JR, Knight DL, Winders K, Nemeroff CB: The serotonergic antidepressant nefazodone inhibits the serotonin transporter: in vivo and ex vivo studies. Life Sci. 1995;57(24):PL373-80.</reference_text>
        <pubmed_id>7475971</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nefazodone</name>
        <accession>HMDB15280</accession>
      </metabolite>
      <reference>
        <reference_text>Owen D, Du L, Bakish D, Lapierre YD, Hrdina PD: Norepinephrine transporter gene polymorphism is not associated with susceptibility to major depression. Psychiatry Res. 1999 Jul 30;87(1):1-5.</reference_text>
        <pubmed_id>10512149</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nefazodone</name>
        <accession>HMDB15280</accession>
      </metabolite>
      <reference>
        <reference_text>Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58.</reference_text>
        <pubmed_id>9537821</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nefazodone</name>
        <accession>HMDB15280</accession>
      </metabolite>
      <reference>
        <reference_text>Taylor DP, Carter RB, Eison AS, Mullins UL, Smith HL, Torrente JR, Wright RN, Yocca FD: Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug.  J Clin Psychiatry. 1995;56 Suppl 6:3-11.</reference_text>
        <pubmed_id>7649970</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nefazodone</name>
        <accession>HMDB15280</accession>
      </metabolite>
      <reference>
        <reference_text>Davis R, Whittington R, Bryson HM: Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression. Drugs. 1997 Apr;53(4):608-36.</reference_text>
        <pubmed_id>9098663</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desipramine</name>
        <accession>HMDB15282</accession>
      </metabolite>
      <reference>
        <reference_text>Zavosh A, Schaefer J, Ferrel A, Figlewicz DP: Desipramine treatment decreases 3H-nisoxetine binding and norepinephrine transporter mRNA in SK-N-SHSY5Y cells. Brain Res Bull. 1999 Jul 1;49(4):291-5.</reference_text>
        <pubmed_id>10424850</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desipramine</name>
        <accession>HMDB15282</accession>
      </metabolite>
      <reference>
        <reference_text>Weinshenker D, White SS, Javors MA, Palmiter RD, Szot P: Regulation of norepinephrine transporter abundance by catecholamines and desipramine in vivo. Brain Res. 2002 Aug 16;946(2):239-46.</reference_text>
        <pubmed_id>12137927</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desipramine</name>
        <accession>HMDB15282</accession>
      </metabolite>
      <reference>
        <reference_text>Bryan-Lluka LJ, Bonisch H, Lewis RJ: chi-Conopeptide MrIA partially overlaps desipramine and cocaine binding sites on the human norepinephrine transporter. J Biol Chem. 2003 Oct 10;278(41):40324-9. Epub 2003 Jul 1.</reference_text>
        <pubmed_id>12837768</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desipramine</name>
        <accession>HMDB15282</accession>
      </metabolite>
      <reference>
        <reference_text>Zhu MY, Kyle PB, Hume AS, Ordway GA: The persistent membrane retention of desipramine causes lasting inhibition of norepinephrine transporter function. Neurochem Res. 2004 Feb;29(2):419-27.</reference_text>
        <pubmed_id>15002740</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desipramine</name>
        <accession>HMDB15282</accession>
      </metabolite>
      <reference>
        <reference_text>Ordway GA, Jia W, Li J, Zhu MY, Mandela P, Pan J: Norepinephrine transporter function and desipramine: residual drug effects versus short-term regulation. J Neurosci Methods. 2005 Apr 30;143(2):217-25. Epub 2004 Dec 30.</reference_text>
        <pubmed_id>15814154</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desipramine</name>
        <accession>HMDB15282</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desipramine</name>
        <accession>HMDB15282</accession>
      </metabolite>
      <reference>
        <reference_text>Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58.</reference_text>
        <pubmed_id>9537821</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Guanethidine</name>
        <accession>HMDB15301</accession>
      </metabolite>
      <reference>
        <reference_text>Joyce PI, Atcheson R, Marcus RJ, Heffernan AM, Rowbotham DJ, Lambert DG: Interaction of local anaesthetic agents with the endogenous norepinephrine transporter in SH-SY5Y human neuroblastoma cells. Neurosci Lett. 2001 Jun 15;305(3):161-4.</reference_text>
        <pubmed_id>11403930</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Guanethidine</name>
        <accession>HMDB15301</accession>
      </metabolite>
      <reference>
        <reference_text>Yi E, Love JA: Alpha-adrenergic modulation of synaptic transmission in rabbit pancreatic ganglia. Auton Neurosci. 2005 Oct 30;122(1-2):45-57. Epub 2005 Aug 25.</reference_text>
        <pubmed_id>16126010</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Guanethidine</name>
        <accession>HMDB15301</accession>
      </metabolite>
      <reference>
        <reference_text>Galli A, Blakely RD, DeFelice LJ: Norepinephrine transporters have channel modes of conduction.  Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8671-6.</reference_text>
        <pubmed_id>8710929</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Orphenadrine</name>
        <accession>HMDB15304</accession>
      </metabolite>
      <reference>
        <reference_text>Pubill D, Canudas AM, Pallas M, Sureda FX, Escubedo E, Camins A, Camarasa J: Assessment of the adrenergic effects of orphenadrine in rat vas deferens.  J Pharm Pharmacol. 1999 Mar;51(3):307-12.</reference_text>
        <pubmed_id>10344632</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clomipramine</name>
        <accession>HMDB15372</accession>
      </metabolite>
      <reference>
        <reference_text>Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58.</reference_text>
        <pubmed_id>9537821</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clomipramine</name>
        <accession>HMDB15372</accession>
      </metabolite>
      <reference>
        <reference_text>Jungkun G, Kuss HJ, Gsell W: Long-term effects of tricyclic antidepressants on norepinephrine kinetics in humans. J Neural Transm. 2001;108(3):349-62.</reference_text>
        <pubmed_id>11341486</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ephedrine</name>
        <accession>HMDB15451</accession>
      </metabolite>
      <reference>
        <reference_text>Kobayashi S, Endou M, Sakuraya F, Matsuda N, Zhang XH, Azuma M, Echigo N, Kemmotsu O, Hattori Y, Gando S: The sympathomimetic actions of l-ephedrine and d-pseudoephedrine: direct receptor activation or norepinephrine release? Anesth Analg. 2003 Nov;97(5):1239-45.</reference_text>
        <pubmed_id>14570629</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ephedrine</name>
        <accession>HMDB15451</accession>
      </metabolite>
      <reference>
        <reference_text>McMahon LR, Cunningham KA: Discriminative stimulus effects of (-)-ephedrine in rats: analysis with catecholamine transporter and receptor ligands. Drug Alcohol Depend. 2003 Jun 5;70(3):255-64.</reference_text>
        <pubmed_id>12757963</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ephedrine</name>
        <accession>HMDB15451</accession>
      </metabolite>
      <reference>
        <reference_text>Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR: New insights into the mechanism of action of amphetamines.  Annu Rev Pharmacol Toxicol. 2007;47:681-98.</reference_text>
        <pubmed_id>17209801</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ephedrine</name>
        <accession>HMDB15451</accession>
      </metabolite>
      <reference>
        <reference_text>Sulzer D, Sonders MS, Poulsen NW, Galli A: Mechanisms of neurotransmitter release by amphetamines: a review.  Prog Neurobiol. 2005 Apr;75(6):406-33.</reference_text>
        <pubmed_id>15955613</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dextroamphetamine</name>
        <accession>HMDB15516</accession>
      </metabolite>
      <reference>
        <reference_text>Dlugos A, Freitag C, Hohoff C, McDonald J, Cook EH, Deckert J, de Wit H: Norepinephrine transporter gene variation modulates acute response to D-amphetamine. Biol Psychiatry. 2007 Jun 1;61(11):1296-305. Epub 2007 Jan 17.</reference_text>
        <pubmed_id>17239355</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dextroamphetamine</name>
        <accession>HMDB15516</accession>
      </metabolite>
      <reference>
        <reference_text>Dlugos AM, Hamidovic A, Palmer AA, de Wit H: Further evidence of association between amphetamine response and SLC6A2 gene variants. Psychopharmacology (Berl). 2009 Oct;206(3):501-11.</reference_text>
        <pubmed_id>19727679</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dextroamphetamine</name>
        <accession>HMDB15516</accession>
      </metabolite>
      <reference>
        <reference_text>Burnette WB, Bailey MD, Kukoyi S, Blakely RD, Trowbridge CG, Justice JB Jr: Human norepinephrine transporter kinetics using rotating disk electrode voltammetry. Anal Chem. 1996 Sep 1;68(17):2932-8.</reference_text>
        <pubmed_id>8794928</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methamphetamine</name>
        <accession>HMDB15517</accession>
      </metabolite>
      <reference>
        <reference_text>Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR: New insights into the mechanism of action of amphetamines.  Annu Rev Pharmacol Toxicol. 2007;47:681-98.</reference_text>
        <pubmed_id>17209801</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methamphetamine</name>
        <accession>HMDB15517</accession>
      </metabolite>
      <reference>
        <reference_text>Sulzer D, Sonders MS, Poulsen NW, Galli A: Mechanisms of neurotransmitter release by amphetamines: a review.  Prog Neurobiol. 2005 Apr;75(6):406-33.</reference_text>
        <pubmed_id>15955613</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phendimetrazine</name>
        <accession>HMDB15519</accession>
      </metabolite>
      <reference>
        <reference_text>Rothman RB, Baumann MH: Therapeutic potential of monoamine transporter substrates.  Curr Top Med Chem. 2006;6(17):1845-59.</reference_text>
        <pubmed_id>17017961</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Milnacipran</name>
        <accession>HMDB15602</accession>
      </metabolite>
      <reference>
        <reference_text>Leo RJ, Brooks VL: Clinical potential of milnacipran, a serotonin and norepinephrine reuptake inhibitor, in pain. Curr Opin Investig Drugs. 2006 Jul;7(7):637-42.</reference_text>
        <pubmed_id>16869117</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Milnacipran</name>
        <accession>HMDB15602</accession>
      </metabolite>
      <reference>
        <reference_text>Moret C, Charveron M, Finberg JP, Couzinier JP, Briley M: Biochemical profile of midalcipran (F 2207), 1-phenyl-1-diethyl-aminocarbonyl-2-aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug. Neuropharmacology. 1985 Dec;24(12):1211-9.</reference_text>
        <pubmed_id>3005901</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mianserin</name>
        <accession>HMDB15620</accession>
      </metabolite>
      <reference>
        <reference_text>Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58.</reference_text>
        <pubmed_id>9537821</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Droxidopa</name>
        <accession>HMDB15627</accession>
      </metabolite>
      <reference>
        <reference_text>Habecker BA, Willison BD, Shi X, Woodward WR: Chronic depolarization stimulates norepinephrine transporter expression via catecholamines. J Neurochem. 2006 May;97(4):1044-51. Epub 2006 Mar 29.</reference_text>
        <pubmed_id>16573647</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Droxidopa</name>
        <accession>HMDB15627</accession>
      </metabolite>
      <reference>
        <reference_text>Bonisch H, Bruss M: The norepinephrine transporter in physiology and disease.  Handb Exp Pharmacol. 2006;(175):485-524.</reference_text>
        <pubmed_id>16722247</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Droxidopa</name>
        <accession>HMDB15627</accession>
      </metabolite>
      <reference>
        <reference_text>Mandela P, Ordway GA: KCl stimulation increases norepinephrine transporter function in PC12 cells.  J Neurochem. 2006 Sep;98(5):1521-30. Epub 2006 Jul 31.</reference_text>
        <pubmed_id>16879714</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Droxidopa</name>
        <accession>HMDB15627</accession>
      </metabolite>
      <reference>
        <reference_text>Gutman DA, Owens MJ: Serotonin and norepinephrine transporter binding profile of SSRIs.  Essent Psychopharmacol. 2006;7(1):35-41.</reference_text>
        <pubmed_id>16989291</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Droxidopa</name>
        <accession>HMDB15627</accession>
      </metabolite>
      <reference>
        <reference_text>Ksiazek P, Buraczynska K, Buraczynska M: Norepinephrine transporter gene (NET) polymorphism in patients with type 2 diabetes. Kidney Blood Press Res. 2006;29(6):338-43. Epub 2006 Nov 23.</reference_text>
        <pubmed_id>17124432</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desvenlafaxine</name>
        <accession>HMDB15646</accession>
      </metabolite>
      <reference>
        <reference_text>Deecher DC, Beyer CE, Johnston G, Bray J, Shah S, Abou-Gharbia M, Andree TH: Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor.  J Pharmacol Exp Ther. 2006 Aug;318(2):657-65. Epub 2006 May 4.</reference_text>
        <pubmed_id>16675639</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desvenlafaxine</name>
        <accession>HMDB15646</accession>
      </metabolite>
      <reference>
        <reference_text>Mason JN, Deecher DC, Richmond RL, Stack G, Mahaney PE, Trybulski E, Winneker RC, Blakely RD: Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter. J Pharmacol Exp Ther. 2007 Nov;323(2):720-9. Epub 2007 Aug 2.</reference_text>
        <pubmed_id>17673606</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desvenlafaxine</name>
        <accession>HMDB15646</accession>
      </metabolite>
      <reference>
        <reference_text>Perry R, Cassagnol M: Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder. Clin Ther. 2009 Jun;31 Pt 1:1374-404.</reference_text>
        <pubmed_id>19698900</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desvenlafaxine</name>
        <accession>HMDB15646</accession>
      </metabolite>
      <reference>
        <reference_text>Kamath J, Handratta V: Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence. Expert Rev Neurother. 2008 Dec;8(12):1787-97.</reference_text>
        <pubmed_id>19086875</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desvenlafaxine</name>
        <accession>HMDB15646</accession>
      </metabolite>
      <reference>
        <reference_text>Liebowitz MR, Tourian KA: Efficacy, safety, and tolerability of Desvenlafaxine 50 mg/d for the treatment of major depressive disorder:a systematic review of clinical trials. Prim Care Companion J Clin Psychiatry. 2010;12(3). pii: PCC.09r00845.</reference_text>
        <pubmed_id>20944767</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desvenlafaxine</name>
        <accession>HMDB15646</accession>
      </metabolite>
      <reference>
        <reference_text>Reddy S, Kane C, Pitrosky B, Musgnung J, Ninan PT, Guico-Pabia CJ: Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician. Curr Med Res Opin. 2010 Jan;26(1):139-50.</reference_text>
        <pubmed_id>19919295</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexmethylphenidate</name>
        <accession>HMDB15647</accession>
      </metabolite>
      <reference>
        <reference_text>Markowitz JS, Patrick KS: Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter? J Clin Psychopharmacol. 2008 Jun;28(3 Suppl 2):S54-61.</reference_text>
        <pubmed_id>18480678</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexmethylphenidate</name>
        <accession>HMDB15647</accession>
      </metabolite>
      <reference>
        <reference_text>Ding YS, Fowler JS, Volkow ND, Dewey SL, Wang GJ, Logan J, Gatley SJ, Pappas N: Chiral drugs: comparison of the pharmacokinetics of [11C]d-threo and L-threo-methylphenidate in the human and baboon brain. Psychopharmacology (Berl). 1997 May;131(1):71-8.</reference_text>
        <pubmed_id>9181638</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexmethylphenidate</name>
        <accession>HMDB15647</accession>
      </metabolite>
      <reference>
        <reference_text>Davids E, Zhang K, Tarazi FI, Baldessarini RJ: Stereoselective effects of methylphenidate on motor hyperactivity in juvenile rats induced by neonatal 6-hydroxydopamine lesioning. Psychopharmacology (Berl). 2002 Feb;160(1):92-8. Epub 2001 Dec 18.</reference_text>
        <pubmed_id>11862378</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexmethylphenidate</name>
        <accession>HMDB15647</accession>
      </metabolite>
      <reference>
        <reference_text>Yang L, Wang YF, Li J, Faraone SV: Association of norepinephrine transporter gene with methylphenidate response.  J Am Acad Child Adolesc Psychiatry. 2004 Sep;43(9):1154-8.</reference_text>
        <pubmed_id>15322419</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexmethylphenidate</name>
        <accession>HMDB15647</accession>
      </metabolite>
      <reference>
        <reference_text>Williard RL, Middaugh LD, Zhu HJ, Patrick KS: Methylphenidate and its ethanol transesterification metabolite ethylphenidate: brain disposition, monoamine transporters and motor activity. Behav Pharmacol. 2007 Feb;18(1):39-51.</reference_text>
        <pubmed_id>17218796</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexmethylphenidate</name>
        <accession>HMDB15647</accession>
      </metabolite>
      <reference>
        <reference_text>Chuhan YS, Taukulis HK: Impairment of single-trial memory formation by oral methylphenidate in the rat.  Neurobiol Learn Mem. 2006 Mar;85(2):125-31. Epub 2005 Oct 24.</reference_text>
        <pubmed_id>16246598</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexmethylphenidate</name>
        <accession>HMDB15647</accession>
      </metabolite>
      <reference>
        <reference_text>Gray JD, Punsoni M, Tabori NE, Melton JT, Fanslow V, Ward MJ, Zupan B, Menzer D, Rice J, Drake CT, Romeo RD, Brake WG, Torres-Reveron A, Milner TA: Methylphenidate administration to juvenile rats alters brain areas involved in cognition, motivated behaviors, appetite, and stress. J Neurosci. 2007 Jul 4;27(27):7196-207.</reference_text>
        <pubmed_id>17611273</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexmethylphenidate</name>
        <accession>HMDB15647</accession>
      </metabolite>
      <reference>
        <reference_text>Sandoval V, Riddle EL, Ugarte YV, Hanson GR, Fleckenstein AE: Methamphetamine-induced rapid and reversible changes in dopamine transporter function: an in vitro model. J Neurosci. 2001 Feb 15;21(4):1413-9.</reference_text>
        <pubmed_id>11160413</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexmethylphenidate</name>
        <accession>HMDB15647</accession>
      </metabolite>
      <reference>
        <reference_text>Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58.</reference_text>
        <pubmed_id>9537821</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexmethylphenidate</name>
        <accession>HMDB15647</accession>
      </metabolite>
      <reference>
        <reference_text>Tilley MR, Gu HH: The effects of methylphenidate on knockin mice with a methylphenidate-resistant dopamine transporter. J Pharmacol Exp Ther. 2008 Nov;327(2):554-60. Epub 2008 Aug 12.</reference_text>
        <pubmed_id>18698001</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levonordefrin</name>
        <accession>HMDB15652</accession>
      </metabolite>
      <reference>
        <reference_text>Habecker BA, Willison BD, Shi X, Woodward WR: Chronic depolarization stimulates norepinephrine transporter expression via catecholamines. J Neurochem. 2006 May;97(4):1044-51. Epub 2006 Mar 29.</reference_text>
        <pubmed_id>16573647</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levonordefrin</name>
        <accession>HMDB15652</accession>
      </metabolite>
      <reference>
        <reference_text>Bonisch H, Bruss M: The norepinephrine transporter in physiology and disease.  Handb Exp Pharmacol. 2006;(175):485-524.</reference_text>
        <pubmed_id>16722247</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levonordefrin</name>
        <accession>HMDB15652</accession>
      </metabolite>
      <reference>
        <reference_text>Mandela P, Ordway GA: KCl stimulation increases norepinephrine transporter function in PC12 cells.  J Neurochem. 2006 Sep;98(5):1521-30. Epub 2006 Jul 31.</reference_text>
        <pubmed_id>16879714</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levonordefrin</name>
        <accession>HMDB15652</accession>
      </metabolite>
      <reference>
        <reference_text>Gutman DA, Owens MJ: Serotonin and norepinephrine transporter binding profile of SSRIs.  Essent Psychopharmacol. 2006;7(1):35-41.</reference_text>
        <pubmed_id>16989291</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levonordefrin</name>
        <accession>HMDB15652</accession>
      </metabolite>
      <reference>
        <reference_text>Ksiazek P, Buraczynska K, Buraczynska M: Norepinephrine transporter gene (NET) polymorphism in patients with type 2 diabetes. Kidney Blood Press Res. 2006;29(6):338-43. Epub 2006 Nov 23.</reference_text>
        <pubmed_id>17124432</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
